Is Rocket Lab Stock a Buy Now?
The stock is up 25% off its lows and costs 10% more than before it missed earnings.
Rocket Lab stock is volatile and will remain so. Wait for a pullback to buy.
10 stocks we like better than Rocket Lab USA ›
It's hard to keep a good company down, and Rocket Lab (NASDAQ: RKLB) investors are happy to realize this.
Earlier this month, as you may recall, Rocket Lab shares tumbled after missing on first-quarter earnings but beating on sales and guiding investors lower than expected for Q2. It didn't take the company long to right the rocketship, however. In quick succession, Rocket Lab announced:
A launch contract for the U.S. Air Force Research Laboratory (AFRL) to attempt point-to-point cargo transportation, launching a Neutron reusable rocket from point A on Earth and then landing it at some other point B -- also on Earth.
A separate contract with NASA to launch the "Aspera" astrophysics science mission, which will "study the formation and evolution of galaxies and provide new insights into how the universe works." (Both these missions will launch in 2026. Neither one had a price disclosed.)
The successful launch under an existing contract of a third (of eight total) synthetic aperture radar (SAR) Earth-imaging satellite for Japan's Institute for Q-shu Pioneers of Space, Inc. (iQPS).
And the third (of four) launch and recovery of a W-class space capsule for orbital pharmaceuticals researcher Varda Space Industries.
So it's been a busy week and a half for Rocket Lab, and all this activity has helped lift the stock nearly 25% off its post-earnings lows. In fact, Rocket Lab stock now costs 10% more than it did before investors sold it off on the earnings miss, which again, I should point out, happened less than two weeks ago!
Granted, momentum investors can be a fickle bunch, selling like lemmings when news looks bad and displaying irrational exuberance when a former dog starts to look a bit like a growth stock. Still, this has been quite a roller-coaster ride. And it presents investors with an important question today:
Were investors right to be worried by Rocket Lab's failure to hit its targets a couple of weeks ago? Or is the good news that Rocket Lab has seen in the days since that earnings release good enough to make the stock even more valuable now than it was before "missing earnings"?
As a longtime shareholder in Rocket Lab myself, let me tell you how I look at it. Rocket Lab stock is volatile, but that kind of comes with the territory when investing in unprofitable start-up stocks that are hard to value on the earnings-that-they-don't-have-yet.
It's going to remain volatile, too.
Don't get me wrong. As America's second-most-frequent launcher of rockets, Rocket Lab does stretch the definition of "start-up." Still, the company lost $190 million last year and burned through $116 million in negative free cash flow. According to analysts polled by S&P Global Market Intelligence, moreover, Rocket Lab is still nearly two years away from reporting its first generally accepted accounting principles (GAAP) profit and probably won't generate positive free cash flow before Q3 2026 -- about 18 months away.
That's the bad news. The good news is that Rocket Lab remains on a strong growth track. Once Neutron begins launching regularly, revenues are forecast to explode, quadrupling to more than $1.8 billion by 2027, for example, with GAAP net income passing $300 million and free cash flow hurtling past $500 million.
The question for long-term investors to ask, therefore, is whether it's reasonable to pay $11.8 billion for Rocket Lab today in hopes of seeing $300 million-ish profits (39x 2028 earnings) and $500 million-ish free cash flow (23x 2028 FCF) tomorrow.
And the answer? I believe it actually is reasonable to make this investment, assuming you're willing to accept the risk that Rocket Lab takes longer than expected to hit these numbers and assuming the company's growth rate remains strong after it does so.
That being said, I also think it's reasonable to anticipate Rocket Lab will hit bumps in the road between now and 2028. For example, as recently as 2022, analysts were forecasting Rocket Lab would earn its first profit in 2025. We now know that's not going to happen. It's therefore reasonable to anticipate other complications emerging as well -- a delay in Neutron's first launch to next year, for example, a delay in first profits past 2027, or similar "known unknowns."
With Rocket Lab stock already well off its lows and trading for a rich 27 times trailing earnings, I just don't see a lot of room for error in the stock's valuation today. My advice would be to wait for a pullback and buy only after the margin of safety looks a bit wider.
Before you buy stock in Rocket Lab USA, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab USA wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!*
Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Rich Smith has positions in Rocket Lab USA. The Motley Fool recommends Rocket Lab USA. The Motley Fool has a disclosure policy.
Is Rocket Lab Stock a Buy Now? was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Xerox Holdings (NASDAQ:XRX) shareholders have endured a 47% loss from investing in the stock five years ago
It is a pleasure to report that the Xerox Holdings Corporation (NASDAQ:XRX) is up 43% in the last quarter. But over the last half decade, the stock has not performed well. After all, the share price is down 61% in that time, significantly under-performing the market. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Given that Xerox Holdings didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. In the last five years Xerox Holdings saw its revenue shrink by 4.2% per year. That's not what investors generally want to see. The share price decline of 10% compound, over five years, is understandable given the company is losing money, and revenue is moving in the wrong direction. We don't think anyone is rushing to buy this stock. Ultimately, it may be worth watching - should revenue pick up, the share price might follow. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. You can see what analysts are predicting for Xerox Holdings in this interactive graph of future profit estimates. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Xerox Holdings, it has a TSR of -47% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Xerox Holdings shareholders are down 47% for the year (even including dividends), but the market itself is up 16%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Xerox Holdings better, we need to consider many other factors. Take risks, for example - Xerox Holdings has 2 warning signs (and 1 which is concerning) we think you should know about. Xerox Holdings is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Leslie's, Inc.'s (NASDAQ:LESL) Intrinsic Value Is Potentially 66% Above Its Share Price
Using the 2 Stage Free Cash Flow to Equity, Leslie's fair value estimate is US$0.69 Leslie's is estimated to be 40% undervalued based on current share price of US$0.42 The US$1.37 analyst price target for LESL is 98% more than our estimate of fair value In this article we are going to estimate the intrinsic value of Leslie's, Inc. (NASDAQ:LESL) by taking the forecast future cash flows of the company and discounting them back to today's value. This will be done using the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex. Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Levered FCF ($, Millions) US$14.0m US$19.0m US$15.6m US$13.8m US$12.8m US$12.2m US$12.0m US$11.9m US$12.0m US$12.1m Growth Rate Estimate Source Analyst x1 Analyst x1 Est @ -17.88% Est @ -11.64% Est @ -7.26% Est @ -4.20% Est @ -2.06% Est @ -0.56% Est @ 0.49% Est @ 1.23% Present Value ($, Millions) Discounted @ 12% US$12.5 US$15.3 US$11.2 US$8.9 US$7.4 US$6.3 US$5.6 US$5.0 US$4.5 US$4.0 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$81m The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 12%. Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = US$12m× (1 + 2.9%) ÷ (12%– 2.9%) = US$144m Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$144m÷ ( 1 + 12%)10= US$48m The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$129m. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of US$0.4, the company appears quite undervalued at a 40% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Leslie's as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 12%, which is based on a levered beta of 2.000. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for Leslie's Strength No major strengths identified for LESL. Weakness Interest payments on debt are not well covered. Opportunity Expected to breakeven next year. Has sufficient cash runway for more than 3 years based on current free cash flows. Good value based on P/S ratio and estimated fair value. Significant insider buying over the past 3 months. Threat Debt is not well covered by operating cash flow. Total liabilities exceed total assets, which raises the risk of financial distress. Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price sitting below the intrinsic value? For Leslie's, there are three fundamental factors you should look at: Risks: For example, we've discovered 4 warning signs for Leslie's (2 are a bit unpleasant!) that you should be aware of before investing here. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for LESL's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $359.72 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
What Is Five Below, Inc.'s (NASDAQ:FIVE) Share Price Doing?
Five Below, Inc. (NASDAQ:FIVE), is not the largest company out there, but it saw a significant share price rise of 138% in the past couple of months on the NASDAQGS. The recent jump in the share price has meant that the company is trading at close to its 52-week high. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. But what if there is still an opportunity to buy? Let's take a look at Five Below's outlook and value based on the most recent financial data to see if the opportunity still exists. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. According to our valuation model, Five Below seems to be fairly priced at around 18% below our intrinsic value, which means if you buy Five Below today, you'd be paying a reasonable price for it. And if you believe that the stock is really worth $161.24, then there isn't much room for the share price grow beyond what it's currently trading. So, is there another chance to buy low in the future? Given that Five Below's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. View our latest analysis for Five Below Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by a double-digit 13% over the next couple of years, the outlook is positive for Five Below. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? It seems like the market has already priced in FIVE's positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value? Are you a potential investor? If you've been keeping an eye on FIVE, now may not be the most optimal time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. If you want to dive deeper into Five Below, you'd also look into what risks it is currently facing. In terms of investment risks, we've identified 1 warning sign with Five Below, and understanding it should be part of your investment process. If you are no longer interested in Five Below, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
